Compare Sun Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STRIDES PHARMA SCIENCE SUN PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 28.6 15.6 183.3% View Chart
P/BV x 2.5 0.9 267.9% View Chart
Dividend Yield % 0.6 0.5 122.7%  

Financials

 SUN PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
SUN PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6791,147 59.2%   
Low Rs375642 58.5%   
Sales per share (Unadj.) Rs121.1317.2 38.2%  
Earnings per share (Unadj.) Rs13.47.8 170.5%  
Cash flow per share (Unadj.) Rs20.725.1 82.6%  
Dividends per share (Unadj.) Rs2.752.00 137.5%  
Dividend yield (eoy) %0.50.2 233.3%  
Book value per share (Unadj.) Rs172.6274.3 62.9%  
Shares outstanding (eoy) m2,399.2689.50 2,680.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.8 154.3%   
Avg P/E ratio x39.4114.0 34.6%  
P/CF ratio (eoy) x25.535.7 71.4%  
Price / Book Value ratio x3.13.3 93.6%  
Dividend payout %20.625.5 80.6%   
Avg Mkt Cap Rs m1,264,65080,058 1,579.7%   
No. of employees `00017.52.5 698.1%   
Total wages/salary Rs m59,6714,341 1,374.7%   
Avg. sales/employee Rs Th16,608.111,325.8 146.6%   
Avg. wages/employee Rs Th3,409.61,731.4 196.9%   
Avg. net profit/employee Rs Th1,833.8280.1 654.8%   
INCOME DATA
Net Sales Rs m290,65928,394 1,023.7%  
Other income Rs m10,255941 1,090.3%   
Total revenues Rs m300,91429,334 1,025.8%   
Gross profit Rs m63,0763,965 1,590.7%  
Depreciation Rs m17,5331,540 1,138.2%   
Interest Rs m5,5531,962 282.9%   
Profit before tax Rs m50,2461,403 3,580.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-12,144-436 2,786.6%   
Tax Rs m6,00997 6,175.5%   
Profit after tax Rs m32,093702 4,571.0%  
Gross profit margin %21.714.0 155.4%  
Effective tax rate %12.06.9 172.5%   
Net profit margin %11.02.5 446.5%  
BALANCE SHEET DATA
Current assets Rs m310,69224,836 1,251.0%   
Current liabilities Rs m173,39618,993 912.9%   
Net working cap to sales %47.220.6 229.5%  
Current ratio x1.81.3 137.0%  
Inventory Days Days9971 139.6%  
Debtors Days Days112113 98.4%  
Net fixed assets Rs m232,47734,289 678.0%   
Share capital Rs m2,399895 268.1%   
"Free" reserves Rs m411,69123,651 1,740.7%   
Net worth Rs m414,09124,546 1,687.0%   
Long term debt Rs m15,22615,513 98.1%   
Total assets Rs m646,93865,437 988.6%  
Interest coverage x10.01.7 585.9%   
Debt to equity ratio x00.6 5.8%  
Sales to assets ratio x0.40.4 103.5%   
Return on assets %5.84.1 142.9%  
Return on equity %7.82.9 271.0%  
Return on capital %10.26.9 147.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02515,697 420.6%   
Fx outflow Rs m38,610735 5,250.2%   
Net fx Rs m27,41514,962 183.2%   
CASH FLOW
From Operations Rs m21,9651,871 1,174.1%  
From Investments Rs m-6,8135,826 -116.9%  
From Financial Activity Rs m-27,305-10,157 268.8%  
Net Cashflow Rs m-8,442-2,615 322.8%  

Share Holding

Indian Promoters % 63.7 27.7 230.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 37.8 13.6%  
FIIs % 23.0 8.6 267.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 25.9 32.0%  
Shareholders   133,026 56,241 236.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 17, 2019 10:01 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS